- Home
- TSHA vs MCRI Comparison
TSHA vs MCRI Comparison
Compare TSHA & MCRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TSHA | MCRI |
|---|---|---|
| Founded | 2019 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | TSHA | MCRI |
|---|---|---|
| Price | $5.70 | $117.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | $11.63 | ★ $111.50 |
| AVG Volume (30 Days) | ★ 2.2M | 109.5K |
| Earning Date | 05-06-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.00% |
| EPS Growth | 5.56 | ★ 41.41 |
| EPS | N/A | ★ 1.52 |
| Revenue | $9,773,000.00 | ★ $395,377,000.00 |
| Revenue This Year | N/A | $4.85 |
| Revenue Next Year | $1,152.42 | $2.21 |
| P/E Ratio | ★ N/A | $79.24 |
| Revenue Growth | 17.28 | ★ 114.40 |
| 52 Week Low | $2.72 | $88.13 |
| 52 Week High | $7.30 | $135.93 |
Technical Indicators
Market Signals| Indicator | TSHA | MCRI |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 32.73 |
| Support Level | $5.72 | $112.85 |
| Resistance Level | $6.01 | $121.15 |
| Average True Range (ATR) | 0.29 | 2.57 |
| MACD | -0.06 | -0.59 |
| Stochastic Oscillator | 22.34 | 9.43 |
Price Performance
Historical ComparisonAbout TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.